TrialJournal for immunotherapy of cancer2017

Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma.

Rahima Jamal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.